Abstract Number: 2254 • ACR/ARHP Annual Meeting 2018
Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, but are limited by their immunogenicity. We have previously shown that synthetic…
ACR Meeting Abstracts